Rethinking Ovarian Cancer: Recommendations for Improving Outcomes

Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.

Abstract

There have been major advances in our understanding of the cellular and molecular biology of the human malignancies that are collectively referred to as ovarian cancer. At a recent Helene Harris Memorial Trust meeting, an international group of researchers considered actions that should be taken to improve the outcome for women with ovarian cancer. Nine major recommendations are outlined in this Opinion article.

Trial registration: ClinicalTrials.gov NCT00262847 NCT00434642 NCT00483782.

Publication types

  • Consensus Development Conference
  • Guideline
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials as Topic
  • Female
  • Health Planning Guidelines
  • Humans
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / genetics
  • Ovarian Neoplasms* / metabolism
  • Ovarian Neoplasms* / prevention & control
  • Practice Guidelines as Topic
  • Treatment Outcome

Substances

  • Antineoplastic Agents

Associated data

  • ClinicalTrials.gov/NCT00262847
  • ClinicalTrials.gov/NCT00434642
  • ClinicalTrials.gov/NCT00483782